Daxing Xie

Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability

D. Ma, Gang Chen, Q. Gao, 2005, Clinical Cancer Research.

DAB2IP suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination in colon cancer.

J. Gong, Liang Liu, Jiao Deng, 2022, Cancer letters.

DAB2IP inhibits p53 ubiquitin-mediated degradation by competitively binding to GRP75 and suppresses tumor malignancy in colon cancer

Xiao-lan Li, D. Tao, J. Gong, 2021, bioRxiv.

Correction: Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability

D. Ma, Gang Chen, Q. Gao, 2005, Clinical Cancer Research.

DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1

R. Kittler, Guanghua Xiao, Jichen Yang, 2014, Oncogene.

The role of DAB2IP in androgen receptor activation during prostate cancer progression

M. Gleave, L. Fazli, W. Min, 2014, Oncogene.